<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241618</url>
  </required_header>
  <id_info>
    <org_study_id>994058402</org_study_id>
    <secondary_id>AI054887</secondary_id>
    <secondary_id>AI41563</secondary_id>
    <secondary_id>Fulbright</secondary_id>
    <secondary_id>TEMPUS</secondary_id>
    <secondary_id>ISID</secondary_id>
    <nct_id>NCT00241618</nct_id>
  </id_info>
  <brief_title>Timing and Duration of Acute Hepatitis C Treatment</brief_title>
  <official_title>Phase IV Study of Treatment of Acute Hepatitis C With Pegylated Interferon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alexander von Humboldt Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fulbright</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>TEMPUS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Society for Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <brief_summary>
    <textblock>
      Spontaneous resolution of acute hepatitis C infection cannot be predicted and the majority of
      cases persist and become chronic. This randomized trial assesses the efficacy and safety of
      peginterferon alfa-2b. The investigators hypothesize that therapy strategies could prevent
      the development of chronic hepatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With nearly 4 million people in the United States, and an estimated 170-200 million people
      worldwide, the hepatitis C virus (HCV) represents a clear and significant public health
      issue. Unfortunately, for most people infected with HCV (70%-85%) spontaneous resolution is
      uncommon and 60% to 80% of patients with acute hepatitis C infection develop chronic
      hepatitis. This randomized trial focuses on defining the effect of treatment of acute HCV on
      prevention of chronic hepatitis in addition to optimization of the treatment regimen, onset
      and the length of peginterferon alpha therapy in acute hepatitis C infections. This
      randomized, multi-center prospective study assesses the efficacy of peginterferon in acute
      hepatitis. We will also compare differences in sustained viral response rates in patients
      with acute hepatitis C starting treatment at 8, 12, or 24 weeks. We will also compare the
      efficacy of 8, 12 or 24 weeks therapy with PEG-IFN-alpha. All eligible patients are enrolled
      and screened for an initial observation period starting from the time of their first positive
      HCV-RNA-PCR, during which bi-weekly serum ALT and HCV-RNA subjects were performed. Patients
      who did not resolve spontaneously (loss of HCV-RNA without treatment) by the end of the
      observation period were randomly assigned to receive PEG-IFN-alpha at the assigned onset
      and/or duration. Patients who do not consent to therapy at enrollment are included as a
      non-randomized comparison group. All subjects with SVR were followed for 48 weeks after the
      follow-up at 24 weeks when SVR was determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date>January 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained viral response rate in treatment group versus control</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>End of treatment virologic response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early virologic response at week 4</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment>180</enrollment>
  <condition>Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alpha 2</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-50 years, with or without symptoms

          -  Diagnosis of acute hepatitis C: elevated serum alanine aminotransferase (ALT) &gt; 10
             times the upper limit of normal (ULN)

          -  Seroconversion from negative to positive anti-HCV antibody status (third-generation
             enzyme-linked immunosorbent assay)

          -  Conversion from negative to positive polymerase chain reaction (PCR) for HCV-RNA,
             ruling out other causes of hepatitis by history and appropriate serologic and
             virologic studies.

        Exclusion Criteria:

          -  Decompensated liver disease

          -  Coinfection with human immunodeficiency virus (HIV) or Schistosoma mansoni

          -  Marked anemia (hemoglobin level ≤ 120 g/L in women and ≤ 130 g/L in men)

          -  Neutropenia (&lt; 1,500/mm3)

          -  Thrombocytopenia (&lt; 90,000/mm3)

          -  A creatinine concentration &gt; 1.5 times ULN

          -  Serum alpha-fetoprotein &gt; 25 ng/ml

          -  An organ transplant

          -  Neoplastic disease

          -  Severe cardiac or pulmonary disease

          -  Unstable thyroid dysfunction

          -  A psychiatric disorder

          -  Seizure disorder

          -  Severe retinopathy

          -  A current pregnancy or were breast feeding or unwillingness to practice contraception

          -  Therapy with immunomodulatory agents within the last 6 months

          -  Alcohol or drug dependence within 1 year of study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alaa Ismail, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanaa M Kamal, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nezam H Afdhal, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manal El Sayed, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ASU</name>
      <address>
        <city>Cairo</city>
        <zip>03316</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASU Specialized Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11351</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shebin Liver Center</name>
      <address>
        <city>Cairo</city>
        <zip>11351</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, Tawil AA, Fehr JJ, Khalifa Kel S, Madwar MM, Koziel MJ. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology. 2004 Jun;39(6):1721-31.</citation>
    <PMID>15185314</PMID>
  </reference>
  <reference>
    <citation>Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003 Jul;125(1):80-8.</citation>
    <PMID>12851873</PMID>
  </reference>
  <reference>
    <citation>Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, Ishibashi H, Kashiwagi S. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004 May;39(5):1213-9.</citation>
    <PMID>15122749</PMID>
  </reference>
  <reference>
    <citation>Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed Khalifa K, Peter T, Mansour H, Ezzat W, Koziel M. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology. 2001 Sep;121(3):646-56.</citation>
    <PMID>11522749</PMID>
  </reference>
  <reference>
    <citation>Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, Leandro G, Pastore G. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis. 2003 Feb;35(2):104-13.</citation>
    <PMID>12747629</PMID>
  </reference>
  <reference>
    <citation>Wiegand J, Jäckel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, Fritsch WP, Kubitschke A, Aslan N, Tillmann HL, Manns MP, Wedemeyer H. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology. 2004 Jul;40(1):98-107.</citation>
    <PMID>15239091</PMID>
  </reference>
  <reference>
    <citation>Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA, Madwar MA. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005 Jun;54(6):858-66.</citation>
    <PMID>15888797</PMID>
  </reference>
  <reference>
    <citation>Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP; German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001 Nov 15;345(20):1452-7.</citation>
    <PMID>11794193</PMID>
  </reference>
  <reference>
    <citation>Larghi A, Zuin M, Crosignani A, Ribero ML, Pipia C, Battezzati PM, Binelli G, Donato F, Zanetti AR, Podda M, Tagger A. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology. 2002 Oct;36(4 Pt 1):993-1000.</citation>
    <PMID>12297849</PMID>
  </reference>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2005</study_first_submitted>
  <study_first_submitted_qc>October 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2005</study_first_posted>
  <last_update_submitted>September 7, 2006</last_update_submitted>
  <last_update_submitted_qc>September 7, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2006</last_update_posted>
  <keyword>Clinical trial</keyword>
  <keyword>Randomized</keyword>
  <keyword>Treatment</keyword>
  <keyword>Prospective</keyword>
  <keyword>Parallel Assignment</keyword>
  <keyword>Efficacy Safety Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

